View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
November 16, 2020updated 12 Nov 2020 11:31am

AstraZeneca and Fusion team up on oncology radiopharmaceuticals

Fusion and AstraZeneca are partnering to develop next-generation radiopharmaceuticals for cancer. Under the terms of the agreement, they will work to combine alpha isotopes with AstraZeneca antibodies to create targeted alpha therapies, as well as linking up with other immunotherapy approaches to improve cancer care, particularly for solid tumours.

By Allie Nawrat

US-Canadian Fusion Pharmaceuticals is collaborating with Anglo-Swedish pharma giant AstraZeneca to develop next-generation radiopharmaceuticals, known as targeted alpha therapies (TATs), to treat cancer.

For this partnership, “Fusion will bring the radioisotope and linker technology, as well as expertise in radiopharmaceutical development, manufacturing and supply chain,” explains the company’s CEO John Valliant. Fusion’s Fast-Clear linker technology allows for isotopes to be delivered to tumour cells and also be rapidly cleared from the body.

Valliant adds: “AstraZeneca will bring…their industry-leading antibody portfolio and oncology expertise.”

AstraZeneca Oncology research and development senior vice-president and head of research and early development Susan Galbraith noted in a release: “With this collaboration, we will seek to identify synergies between our pipelines to unlock the full potential of our medicines, and also to develop novel targeted radiopharmaceuticals.

“We believe that the Fusion team’s expertise in next-generation radiopharmaceuticals complements AstraZeneca’s extensive research and development portfolio.”

According to the terms of the agreement, Fusion and AstraZeneca will jointly discover, develop and have the option to co-commercialise the novel TATs in the US. Fusion will receive an upfront payment from AstraZeneca and will also be eligible for future development milestone and other payments.

Although clinical costs will be shared, Fusion will be responsible for pre-clinical development, while AstraZeneca will take over for the clinical stages of development.

Spotlight on Fusion’s radiopharmaceuticals

Radiotherapy has been the standard of care for many cancers for decades. However, Fusion aims to take this principle and make it more targeted with radiopharmaceuticals that precisely deliver radiation to cancer cells, explains Vaillant.

Focused on alpha-emitting radiopharmaceuticals, Fusion used its proprietary Fast-Clear Linker technology to combine alpha radiation with targeting molecules, such as antibodies. These TATs “cause substantial physical damage to cancer cells, including multiple double-stranded DNA breaks that are lethal to the tumour”, Valliant notes.

TATs also have multiple mechanisms of action that “may give them the ability to treat hard-to-treat solid tumours”. Further to this, they also cause “the release of tumour-associated antigens and concomitant maturation of antigen-presenting cells and proliferated T cells at tumour sites, leading to an enhanced immune response to go along with the physical damage by the alpha radiation”, adds Valliant.

Combination therapies

Valliant explains that another element of the multi-pronged mechanism of action of the company’s TATs is that they have “the potential to work synergistically with other approved oncology therapies”.

He continues that preclinical studies have suggested that combining TATs with checkpoint inhibitors might cause a “robust therapeutic effect in solid tumours compared to checkpoint inhibitor monotherapies”. There is also promise of combining TATs with DNA damage response inhibitors.

Given these promising potential combinations, in addition to developing novel TATs by linking AstraZeneca antibodies with alpha-emitting isotope Actinium225, Fusion and AstraZeneca are also working on combining the former’s lead TAT candidate FPI-1434 with other oncology therapeutics in the latter’s portfolio.

Valliant notes: “Together we will explore new combination therapies, including evaluating the synergy of the DNA-damaging and neoantigen-creating power of TATs with DNA damage repair inhibitors and immuno-oncology agents to create new and potent cancer therapies and treatment paradigms.”

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology